Sequencing MDx Firm Sequenta Raises $20M in Series C Round | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenta has completed a Series C financing round, raising $20 million, it said on Tuesday.

Proceeds will go toward the commercial scale-up and clinical validation of its next-generation sequencing-based ClonoSight Test for minimal residual disease in leukemia and lymphoma.

Foresite Capital Management led the round, and all inside investors participated, Sequenta said, including MDV and Index Ventures. In addition, Jim Tananbaum, managing director of Foresite Capital, has joined Sequenta's board.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.